The price you pay for Soliris may depend on factors such as whether you have health insurance. Financial assistance may be available to help you with the cost of Soliris. your treatment plan your ...
Things haven’t gone Alexion’s way lately: After investors cheered the possibility of an Amgen merger, the hoped-for partner advanced its Soliris patent challenge. The possibility of losing that ...
Alexion nabs potential $1B indication for Soliris, but it'll have to take on Roche's cheaper Rituxan
In an effort to protect its blockbuster Soliris, Alexion has employed a double strategy of nabbing additional approvals and positioning follow-up drug Ultomiris to switch over sales. Alexion added ...
Alexion's Soliris Granted Marketing Approval in Europe for Treatment of All Patients With PNH - First therapy approved in both Europe and the United States for rare and life-threatening blood disease ...
The FDA approved a fourth indication for Alexion Pharmaceuticals’ brand-name eculizumab (Soliris) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are ...
Apellis Pharmaceuticals’ pegcetacoplan has beaten Alexion’s blockbuster Soliris in a head-to-head phase 3 trial. The result suggests Apellis can challenge Alexion’s dominance in paroxysmal nocturnal ...
- 98% of adult anti-aquaporin-4 (AQP4) antibody-positive patients treated with SOLIRIS were relapse free compared to 63% receiving placebo at 48 weeks - “We are pleased that the Japanese health ...
Update: On September 29, 2021, Canada applied to the Supreme Court of Canada for leave to appeal (Docket No. 39858). According to the Board’s Guidelines, as a breakthrough drug, the highest price at ...
In the PREVENT study, the safety and efficacy of Soliris was compared to placebo in patients with AQP4 auto antibody-positive NMOSD (N=143). Treatment with Soliris (eculizumab; Alexion) was associated ...
(Reuters) - The U.S. patent office will review patents on Alexion Pharmaceuticals Inc's blood disorder treatment Soliris, after Amgen Inc challenged them, court filings showed on Friday. The move ...
(CBS) The FDA has approved the drug Soliris (eculizumab) for the treatment of a rare and potentially deadly blood disease known as atypical hemolytic uremic syndrome (aHUS). There are no other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback